Personalized cancer therapy is becoming more histology agnostic as treatments are chosen based on tumor genomics rather than tumor type.1,2 Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor that belongs to the epidermal growth factor receptor family and is encoded by the ERBB2 (HER2) gene (chromosome 17q12). This evidence concerns the gene ERBB2 and neoplasm.